evipedia.aidev
← Back

Manuka Honey for Health & Longevity

Evidence Review created on 09/04/2026 using AI4L / GPT 5.6

Also known as: Mānuka Honey, Leptospermum scoparium Honey

Motivation

Manuka honey is made mainly from nectar collected from manuka shrubs in New Zealand and Australia. It has unusually strong and measurable activity against some bacteria. This has created two distinct uses: a costly food eaten for general wellness, and specially prepared products placed on wounds, eyelids, or other body surfaces. Evidence for one use cannot be assumed to apply to the other.

Honey has a long history in wound care. Modern interest grew when researchers found that manuka honey retained some antibacterial activity after one common honey pathway was blocked. Human research now focuses mainly on wounds, dry eye, and mouth conditions. Popular healthy-aging claims go much further, proposing broad benefits from daily consumption. The resulting market also blurred important distinctions between food honey, sterile medical products, and formulations tested for particular conditions.

This review examines reported human outcomes, laboratory findings, product types, sugar exposure, unwanted effects, and quality control. It distinguishes supervised medical use from eating retail honey and assesses whether evidence from tests on cells or bacteria translates into meaningful improvements in health, function, or length of life.

Benefits - Risks - Protocol - Conclusion

This selection provides accessible overviews of manuka honey’s clinical uses, mechanisms, and limits.

No directly relevant item was found from Rhonda Patrick, Peter Attia, or Andrew Huberman. Five sources qualified without padding the list with general honey or commercial product pages.

Grokipedia

Mānuka honey

Provides a broad reference overview of origin, chemistry, grading, proposed uses, regulation, and controversies; its claims still require checking against primary clinical literature.

Examine

No dedicated Examine article for Manuka Honey was identified by indexed-site search; direct on-site confirmation was unavailable because Examine returned a security checkpoint.

ConsumerLab

Manuka Honey Review & Top Picks

Summarizes independent product testing, labeling, safety, and clinical evidence; detailed ratings require membership, while the public summary identifies the review’s scope.

Systematic Reviews

These reviews synthesize evidence for dry eye, chronic rhinosinusitis (long-lasting sinus inflammation), and infections that resist antibiotics—the most studied manuka-honey applications.

No intervention-specific systematic review primarily evaluated long-term metabolic harms, dental caries, or allergy; those trade-offs are unrepresented here.

Mechanism of Action

Manuka honey is concentrated sugar with low water availability and an acidic pH (a measure of acidity), conditions that draw water from microbes and impair growth. Dilution can activate glucose oxidase (an enzyme that converts glucose into acid and hydrogen peroxide), adding peroxide-dependent antimicrobial activity. Its distinguishing non-peroxide component is methylglyoxal, a reactive small molecule formed from dihydroxyacetone in manuka nectar. Methylglyoxal can modify microbial proteins and DNA (the molecule that stores genetic information); concentration generally tracks labeled antibacterial potency, although the laboratory assay and the treated tissue also matter.

Topically, viscous honey maintains a moist interface, may assist removal of dead tissue through osmotic fluid movement, and can reduce odor. A review of wound research describes changes in inflammatory signaling, immune-cell recruitment, and tissue repair. These mechanisms can pull in opposite directions: low concentrations may support repair, whereas concentrated methylglyoxal can damage mammalian cells in laboratory conditions. Sterilization, dilution by wound fluid or tears, contact time, and formulation therefore alter both activity and tolerability.

Oral honey is digested principally as glucose and fructose. Methylglyoxal is chemically reactive and extensively transformed; there is no established oral distribution, half-life, or tissue exposure that connects retail consumption with systemic antimicrobial or longevity effects. Laboratory bacterial inhibition and antioxidant assays are therefore mechanistic signals, not evidence of infection treatment, cancer prevention, or longer life.

Historical Context & Evolution

Honey was used on wounds in multiple ancient medical traditions, primarily as a readily available dressing rather than a standardized drug. Manuka is the Māori name for shrubs including Leptospermum scoparium. The honey was once a relatively low-value regional product. The original New Zealand honey survey found that manuka samples retained substantial antibacterial activity after hydrogen peroxide activity was neutralized; a later review by Peter Molan describes the subsequent wound research.

Commercial grading followed. The Unique Manuka Factor system initially represented an antibacterial laboratory comparison and later incorporated chemical identity and quality markers. Direct methylglyoxal labels report a concentration rather than a clinical dose. These systems helped create a premium international food market, but neither proves a health outcome. Medical-grade honey products were separately sterilized and engineered as dressings, gels, or eye products, creating a clinically different category from jarred honey.

Scientific interest moved from laboratory killing of bacteria toward clinical testing. Outcomes became application-specific: a diabetic-foot-ulcer trial (foot wounds associated with diabetes) and dry-eye review suggested benefit, whereas a venous-leg-ulcer trial (lower-leg wounds linked to impaired vein blood flow) and postoperative sinus review did not establish broad superiority. The evolution is therefore not from traditional remedy to universally validated treatment; it is from an unstandardized food to testable formulations whose effects depend on route, comparator, and condition.

Expected Benefits

High 🟩 🟩 🟩

Dry-Eye Symptom and Surface Improvement

A meta-analysis of five randomized trials involving 288 adults found improvements across symptom scores, tear evaporation, surface staining, and lubricant use with formulated topical manuka products. Methodological limitations reduce certainty, and this evidence does not apply to putting food-grade honey in the eye.

Magnitude: In adults using formulated topical manuka products for dry eye, outcomes favored manuka over controls across several measures, but the abstract reports no pooled figure; scales, formulations, and follow-up differed.

Medium 🟩 🟩

Dry-Mouth Relief in Older Adults

A single randomized trial in 42 older adults compared manuka rinse, natural-honey rinse, and saline for one month. Symptoms, clinical dryness, salivary flow, and oral-health quality of life improved most with manuka, but replication is absent.

Magnitude: At one month, the manuka group had a subjective dryness score of 2 ± 0.39, clinical dryness score of 5.71 ± 0.91, and salivary flow of 1.51 ± 0.34 versus 1.01 ± 0.19 with natural honey and 0.81 ± 0.19 with saline.

Reduced Gum Plaque and Bleeding

A 21-day randomized pilot in 30 volunteers compared a manuka “honey leather” with sugar-free gum. Plaque and bleeding fell only in the honey group, but the tiny study lacks replication and did not measure cavities.

Magnitude: Mean plaque score fell from 0.99 to 0.65, and bleeding sites from 48% to 17%.

Added Gum-Health Improvement During Blood-Filtering Dialysis

A 140-person randomized trial found modest additional gum-health improvement when a manuka rinse accompanied standard nonsurgical care in adults receiving blood-filtering dialysis. This single medically complex cohort requires replication, and whole-body clinical outcomes were not assessed.

Magnitude: At six months, gum attachment to the tooth improved by an additional 0.5 mm versus saline rinse (95% confidence interval 0.14–0.86 mm; a range of values compatible with the data).

Postoperative Allergic-Fungal Sinus Improvement

A 30-person randomized trial compared manuka sinus irrigation with oral itraconazole for six weeks after surgery. Symptoms, endoscopic findings, and allergy-associated antibody levels favored manuka, while imaging and infection outcomes were similar; replication is absent.

Magnitude: Direction favored manuka irrigation for symptoms and endoscopic findings after six weeks, but the abstract reports no between-group outcome figure.

Low 🟩

Wound Healing Across Wound Types ⚠️ Conflicted

Wound effects vary by condition. A 63-person diabetic-foot trial found faster healing, but a 368-person leg-ulcer trial found no significant advantage, and a 21-person roof-of-mouth wound trial found comparable outcomes. The net reading is condition-specific uncertainty rather than a general benefit.

Magnitude: Mean diabetic-foot healing time was 31 ± 4 versus 43 ± 3 days; at 12 weeks, 55.6% versus 49.7% of venous ulcers healed (absolute difference 5.9 percentage points; 95% confidence interval −4.3 to 15.7).

Speculative 🟨

Activity Against Drug-Resistant Bacteria

A systematic review found broad activity in laboratory susceptibility assays, including resistant strains. Human infection outcomes remain inadequate; this is not evidence that honey can replace antibiotics.

Anticancer Activity

A cell-and-mouse study reported growth suppression in breast-cancer models. No controlled human outcome data establish cancer prevention, treatment, or survival benefit, so the basis remains preclinical only.

Systemic Health or Longevity

Antioxidant, anti-inflammatory, microbiome, and lifespan claims rest on laboratory work, animal studies, or extrapolation from other honeys. No human trial demonstrates longer life or broad healthspan improvement from eating manuka honey.

Benefit-Modifying Factors

  • Genetics: No replicated genetic variant is known to modify manuka-honey benefit. Genetic testing currently has no established role in product or dose selection.

  • Baseline markers: No validated biomarker threshold predicts benefit. Baseline tear evaporation, eye-surface staining, salivary flow, wound area, and wound blood flow may define severity and room for improvement, but antibacterial grade alone does not predict an outcome.

  • Sex: Trials include both sexes but do not establish sex-specific efficacy. Sex-based protocol changes are unsupported.

  • Health conditions: Wound cause, blood flow, infection, pressure, glucose control, and standard wound care can dominate outcomes. Eye findings apply mainly to evaporative dry eye, not every cause of ocular discomfort.

  • Age: Older adults were represented in wound and dry-mouth studies, but frailty, impaired healing, diabetes, and medication burden increase the importance of condition-specific clinical care.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Temporary Ocular Stinging and Redness

The five-trial dry-eye review found temporary stinging and redness, generally tolerated, without serious adverse events. High concentrations of dissolved substances, acidity, and reactive constituents provide plausible mechanisms; only sterile products made for eye use were studied.

Magnitude: Not quantified in available studies. The review reported temporary stinging and redness but provided no pooled incidence or between-group effect.

Medium 🟥 🟥

Infant Exposure Through Adult Caregiving

For adults caring for infants, any honey can carry spores that may grow in an infant’s intestine and cause weakness, poor feeding, breathing failure, or death. A review of epidemiologic and case evidence identifies exposure before 12 months as the relevant risk; it is not unique to manuka.

Magnitude: More than 1,000 U.S. infant-botulism cases had been reported when the 2002 review was published; it does not quantify manuka-specific incidence.

More Adverse Events With Leg-Ulcer Dressings

In the large venous-ulcer trial, honey dressings caused more adverse events than usual care without improving healing. Pain or local reactions can make treatment burdensome, particularly on inflamed wounds.

Magnitude: Relative risk (the event-rate ratio between groups) was 1.3 (95% confidence interval 1.1–1.6).

Low 🟥

Gastrointestinal Intolerance With Oral Use ⚠️ Conflicted

Oral use can cause nausea, vomiting, or abdominal discomfort. In a 400-child randomized trial, honey and placebo groups had more vomiting early; a 106-person trial found high, similar nausea-related dropout. These findings establish poor tolerability in vulnerable settings, not a manuka-specific causal effect.

Magnitude: Vomiting increased early without group-specific counts; dropout was 57% with honey versus 52% with placebo, and 78% tolerated study products beyond one week.

Allergy

Honey can contain bee- and plant-derived proteins. The small crossover trial found no rise in total immunoglobulin E (an allergy-associated antibody), but it cannot exclude rare reactions.

Magnitude: Not quantified in available studies. The 20-person trial measured an allergy-associated antibody rather than clinical allergy incidence and was too small to estimate rare reactions.

Speculative 🟨

Added-Sugar and Energy Exposure

Manuka honey remains glucose and fructose. A 20-person crossover safety trial tested 20 g daily for four weeks but did not demonstrate long-term glucose, weight, dental, or cardiovascular harm; this concern is extrapolated from dietary sugar.

Dental Caries With Frequent Oral Exposure

Frequent sugar contact plausibly promotes tooth decay, although a small gum-inflammation trial showed improved plaque and did not measure cavities. The concern is mechanistic and extrapolated from dietary sugar, not demonstrated by manuka-specific outcome trials.

Tissue Toxicity at High Local Concentrations

Methylglyoxal can damage mammalian cells in laboratory systems. Clinical relevance is uncertain because medical formulations, dilution, and wound fluid alter exposure; controlled human tissue-injury evidence is absent.

Microbial Exposure From Raw Honey

Raw honey may contain viable microbes that pose greater risk during immunosuppression (weakened immune defenses). This concern rests on contamination biology and isolated reports; controlled manuka-specific outcome data are absent.

Delayed Effective Treatment

Using honey alone can delay diagnosis, antibiotic treatment, blood-flow restoration, pressure relief, or eye care. No controlled manuka-specific study quantifies this pathway, so the basis is clinical plausibility rather than measured human outcomes.

Risk-Modifying Factors

  • Genetics: No validated genetic variant predicts allergy, irritation, metabolic response, or wound complications from manuka honey.

  • Baseline markers: Higher glucose or hemoglobin A1c (a measure of average blood sugar over roughly three months), excess body weight, active dental decay, and uncontrolled wound infection increase concern around sustained oral intake or delayed standard care.

  • Sex: No consistent sex difference in adverse effects has been established; pregnancy changes glucose tolerance but does not create a known manuka-specific interaction.

  • Health conditions: Diabetes, fructose malabsorption (difficulty absorbing fruit sugar), severe pollen or bee-product allergy, compromised wounds, and active eye disease can increase risk or make unsupervised use inappropriate.

  • Age: Infants under 12 months face botulism risk from any honey. Older adults may have slower wound healing, diabetes, fragile skin, or polypharmacy (use of many medications) that raises the cost of delayed effective care.

Key Interactions & Contraindications

  • Glucose-lowering medications (insulin, metformin, and sulfonylureas): caution; monitor. Sulfonylureas (older medications that prompt insulin release; examples include glipizide and gliclazide) and oral honey can alter glucose control. Portion consistency and glucose tracking mitigate unexpected changes; no direct drug-processing interaction is established.

  • Other prescription medications: no established direct interaction. Published interaction evidence is insufficient to support additional human drug-processing cautions; medication review remains relevant when oral honey changes carbohydrate intake or a topical product is added to complex care.

  • Over-the-counter wound antiseptics (hydrogen peroxide, povidone-iodine): caution. Layering products can irritate tissue or alter a medical honey dressing. The wound-care plan determines whether products are combined or separated.

  • Other sweetened supplements: caution. Honey-containing herbal syrups, gummies, and carbohydrate powders have additive sugar and energy exposure. Total intake, rather than antibacterial grade, determines this consequence.

  • Antibiotics (amoxicillin, doxycycline) and standard dressings: caution; substitution is unsupported. Laboratory antibacterial activity does not establish replacement efficacy. Deep or spreading infection is assessed with culture where appropriate and condition-specific treatment rather than relying on honey alone.

Populations who should avoid Manuka Honey:

  • Infants under 12 months, because all honey can contain Clostridium botulinum spores.
  • People with a prior serious reaction to honey or bee products.
  • People considering food-grade honey in an eye, sinus, deep wound, burn, surgical site, or device entry site.
  • People with a spreading infection, fever, tissue death, impaired circulation, or a diabetic foot wound outside professional wound care.

Risk Mitigation Strategies

  • Match formulation to route: Sterile, purpose-made products prevent contamination and tissue injury when honey is used on wounds or eyelids; retail honey is a food, not an eye-care or wound product.

  • Account for carbohydrate: Recording grams and substituting rather than adding oral honey limits glucose, energy, weight, and dental risks. One tablespoon contains roughly 17 g carbohydrate.

  • Allergic-symptom response: Discontinuation after hives, swelling, wheeze, or breathing difficulty limits continued allergen exposure; urgent assessment is the standard response to severe reactions.

  • Wound warning-sign response: Same-day assessment for spreading redness, fever, increasing pain, odor, tissue darkening, or poor circulation prevents honey use from delaying infection or blood-flow treatment.

  • Eye-product selection: Purpose-made sterile eye products, rather than jarred honey, mitigate abrasion, infection, and chemical irritation; persistent pain or vision change is a reason for prompt eye assessment.

  • Early reassessment: Comparison of a prespecified symptom or wound measure after 2–4 weeks limits prolonged expense, irritation, and ineffective use.

Therapeutic Protocol

  • Standard specialist wound protocol: Sterile medical-grade gel or impregnated dressings are used within wound care that also addresses compression, pressure relief, blood supply, infection, dead tissue, and dressing changes according to wound fluid.

  • Protocol provenance: A review by Peter Molan summarizes University of Waikato research behind modern medical-honey wound practice; no single clinic or practitioner popularized the condition-specific eye, sinus, and oral regimens tested later.

  • Competing approaches: Dry-eye care can use lubricants and eyelid care alone or add a formulated manuka product; wound care can use standard dressings or add medical honey. Evidence does not establish one approach across conditions.

  • General oral wellness: No practitioner-endorsed, evidence-based longevity protocol exists. A healthy-adult trial used 20 g daily for four weeks; this established only short-term tolerability, not benefit.

  • Dry eye: A five-trial review evaluated sterile proprietary gels or 16% eye drops, commonly alongside standard care for roughly three weeks. Product instructions and eye-clinician oversight define frequency; food honey was not studied.

  • Wounds: Medical-grade, sterilized honey is supplied in gels or impregnated dressings within wound-care protocols. Dressing frequency depends on fluid, tissue, infection, compression, pressure relief, blood supply, and product instructions.

  • Sinus disease: A systematic review evaluated 16.5% rinses used twice daily for 14–30 days after sinus surgery. Results were not superior, and this route requires specialist oversight and sterile irrigation practice.

  • Timing and division: No best time exists for oral wellness use. Dividing intake prolongs dental sugar exposure; single versus split dosing has not been compared for systemic benefit.

  • Human half-life: Honey is a mixture, so it has no single half-life. Its sugars are rapidly absorbed; no clinically useful methylglyoxal half-life supports oral scheduling.

  • Genetics and sex: No reproducible genetic or sex-based dose adjustment exists.

  • Age and baseline status: Older age, glucose control, oral health, wound blood flow, allergy history, and the diagnosed target condition influence route selection and supervision more than the label grade.

Discontinuation & Cycling

  • Duration: Clinical products are generally short-term and endpoint-based; daily lifelong oral use has not been studied for longevity.

  • Withdrawal: No physiological withdrawal syndrome is known. Stopping added oral honey simply removes its carbohydrate and energy contribution.

  • Tapering: No taper is required. A medical dressing is discontinued or changed according to wound status rather than dose reduction.

  • Cycling: No evidence shows that cycling preserves antimicrobial activity or systemic efficacy. Treatment courses in trials reflected the condition and follow-up window.

Sourcing and Quality

  • Identity: New Zealand export rules distinguish monofloral and multifloral mānuka honey through chemical and pollen-related criteria. Traceable origin and lot identification reduce substitution risk.

  • Potency labels: Methylglyoxal labels state milligrams per kilogram; Unique Manuka Factor certification combines potency and identity markers. Neither scale is a demonstrated longevity dose-response measure.

  • Independent verification: Certification, lot-specific laboratory results, tamper-evident packaging, and testing for authenticity, residues, and contaminants are stronger signals than front-label health claims.

  • Medical products: Sterile medical-grade gels and dressings such as MediHoney, and purpose-made eye products such as Optimel, differ fundamentally from edible jars. Regulatory clearance is product- and indication-specific.

  • Storage: A sealed container protected from excess heat and moisture preserves quality. Heating can change enzymes and chemical markers; home processing cannot create medical sterility.

Practical Considerations

  • Time to effect: Dry-eye trials assessed about three weeks; wound trials followed healing over weeks; oral wellness and longevity effects have no established timeline.

  • Common pitfall: Extrapolating a methylglyoxal number or laboratory bacterial result to oral systemic benefit confuses chemical potency with a demonstrated clinical outcome.

  • Route confusion: Eating retail honey, applying sterile medical honey, and using a formulated eye product are separate interventions with noninterchangeable evidence.

  • Regulatory status: Retail honey is food. The United States Food and Drug Administration (FDA) and corresponding authorities elsewhere regulate medical-honey dressings and eye products by intended use; food labels do not authorize disease treatment.

  • Cost and payer incentives: High-grade honey costs far more than ordinary honey without proven longevity benefit. Access and coverage vary. Payers therefore favor cheaper usual care, a financial incentive that may influence institutional policy and research priorities.

Interaction with Foundational Habits

  • Sleep — indirect: No reliable sleep effect is established. Reflux, glucose excursions, or dental exposure from bedtime intake could be counterproductive; sleep improvement should not be attributed to manuka honey without a reproducible change.

  • Nutrition — potentially blunting: Oral honey adds free sugar and energy without evidence of unique systemic benefit. Substitution for another sweetener differs metabolically from adding it to an otherwise unchanged diet.

  • Exercise — none established: No human evidence shows improved performance, recovery, muscle growth, or adaptation. As carbohydrate, honey can provide fuel, but a premium antibacterial grade has no demonstrated exercise advantage.

  • Stress management — none established: No controlled human evidence shows a direct effect on perceived stress or stress hormones. Ritual or taste may influence subjective experience, but that is not a manuka-specific biological effect.

Monitoring Protocol & Defining Success

For brief topical use, routine laboratory testing is not established; baseline documentation centers on the diagnosed condition, allergy history, photographs or validated symptom score, and current treatment. Sustained oral use makes baseline body weight, waist circumference, fasting glucose, hemoglobin A1c, and dental status reasonable contextual measures because the exposure is an added sugar, not because manuka-specific targets exist.

Reassessment in 2–4 weeks fits most studied topical courses. Wounds require clinician-defined measurement frequency, often at each dressing review; failure of area to contract, increasing pain, spreading redness, or fever prompts earlier reassessment. For ongoing oral intake, weight and home glucose trends can be reviewed at 4–8 weeks and metabolic laboratory tests at about three months, then every 6–12 months if continued. These are general risk markers; no biomarker validates a longevity response to manuka honey.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Fasting glucose 70–90 mg/dL Tracks blood-sugar effect Morning fast; no manuka-specific target; conventional normal is usually 70–99 mg/dL.
Hemoglobin A1c 4.5%–5.2% Tracks longer-term glucose Reflects roughly three months; functional targets vary, while the conventional normal range is below 5.7%; neither is validated as a manuka-response target.
Body weight and waist No universal target; track change from baseline Detects energy surplus Same scale, time, and measurement site; interpret with body composition and overall diet.
Wound area No universal target; track weekly percentage change Quantifies healing Length × width is approximate; depth, drainage, tissue, pain, infection, blood flow, and photographs add context.

Qualitative markers include:

  • Dry-eye symptom score, lubricant use, stinging, redness, and vision change.
  • Wound pain, drainage, odor, surrounding redness, function, and dressing tolerance.
  • Oral dryness, swallowing comfort, taste tolerance, nausea, and dental sensitivity.
  • Any hives, swelling, wheeze, gastrointestinal symptoms, or reproducible glucose excursion.

Emerging Research

  • Post-tonsillectomy pain: NCT06275698 is recruiting 100 participants to test high-methylglyoxal manuka honey for pain after tonsil removal. It could strengthen or weaken an already negative pediatric trial signal.

  • Gum disease during blood-filtering dialysis: NCT06726876 is recruiting 150 participants to evaluate a manuka oral rinse in gum disease among people receiving hemodialysis (blood-filtering treatment), a medically complex group not represented by the early gum-inflammation pilot.

  • Gum-graft healing: NCT07016373 plans 24 participants to examine pain and healing after gum-graft surgery with a manuka-honey approach, extending oral evidence beyond plaque and dry mouth.

  • Needed discriminating evidence: The Wallace et al., 2010 crossover trial found no short-term safety signal but was small. Larger oral studies need ordinary-honey and unsweetened controls plus glucose, dental, gastrointestinal, and patient-important outcomes to separate sweetness, expectancy, and manuka chemistry.

  • Formulation-specific replication: The Hu et al., 2023 dry-eye meta-analysis supports a signal but identifies design limitations. Independent, masked trials could separate product effects from standard care and quantify irritation, durability, and clinically meaningful symptom change.

Conclusion

Manuka honey is not one uniform health intervention. Eaten as food, it is a costly honey made mainly of sugars, and human research does not show that regular use extends life or broadly improves healthy aging. Its ability to slow or kill bacteria is convincing in laboratory tests, but that does not prove it can treat infection throughout the body, prevent cancer, improve gut health, or lengthen life after it is eaten.

The clearest human evidence concerns products made specifically for dry eye. Several small studies report better symptoms and eye-surface health, alongside brief stinging and redness. Some wound and mouth studies are encouraging, but results vary with the condition: diabetic foot wounds may heal faster, whereas leg ulcers related to poor blood flow have shown no clear healing advantage and more unwanted effects. Studies of sinus problems have generally not shown better outcomes.

Product type, cleanliness, method of use, and usual care matter more than a retail strength number. Added sugar, rare allergy, local irritation, uncertain product identity, and delayed effective treatment are the main practical concerns. Commercial promotion and payer preference for cheaper care are potential sources of bias. The overall evidence supports limited potential for selected, purpose-made products rather than daily eating as a healthy-aging strategy; uncertainty remains substantial outside those narrow uses.

Top - Benefits - Risks - Protocol